Niaid DCR operational task order
Ended Awarded Last action
- Contract number
- 75N91024F00012
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $65,313,869
Award facts
- Contract value 94% obligated
- $69,299,577.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $55,103,731 | |
| Original award | $10,210,138 |
About this award
This is a $69,299,577.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The contract supports NIAID's Division of Clinical Research (DCR) operational requirements and has an ultimate completion date of August 30, 2025. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and serves as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI). The contract does not have a set-aside designation. Key subcontractors include Abbott Molecular Inc. for molecular diagnostics equipment and services, Tecan U.S., Inc. for laboratory automation solutions, and The Mitchell Group, Inc. for operational support and management consulting. This contract supports NIAID's critical medical research and clinical programs, leveraging Leidos' expertise in areas such as facilities operations, research and development, clinical trials, and specialized laboratory services.
Quick answers
Who was awarded contract 75N91024F00012?
75N91024F00012 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2024.
How much is contract 75N91024F00012 worth?
The government has obligated $65,313,869 on 75N91024F00012. Its current value, with exercised options, is $69,299,577.
Which agency awarded contract 75N91024F00012?
National Cancer Institute (National Institutes of Health) awarded 75N91024F00012, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91024F00012 an order under another contract?
Yes. 75N91024F00012 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00012 competed?
The extent of competition for 75N91024F00012 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award